The Company has initiated a search for a Chief Financial Officer, and is in the process of hiring a general counsel to assume the role of Mr. Lanham.
Save time and jump to the most important pieces.
4/A - NYMOX PHARMACEUTICAL CORP (0001018735) (Issuer)
4 - NYMOX PHARMACEUTICAL CORP (0001018735) (Issuer)
4 - NYMOX PHARMACEUTICAL CORP (0001018735) (Issuer)
IRVINE, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the "Company") is providing additional information concerning recent changes in the Company's board of directors (the "Board") and management, as well as additional information regarding the Company's conclusion that a potential transaction was not in the best interests of the Nymox and its shareholders. Nymox recently terminated the employment of Mr. Randall Lanham, the Company's former in-house legal counsel, and Mr. Christopher Riley, the Company's former chief financial officer. Mr. Lanham and Mr. Cutler were removed from the Board. Mr. Lanham (legal counsel) and Mr. Riley (CFO)
IRVINE, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the "Company") is pleased to announce the appointment of Patrick Doody as Nymox Vice President, General Counsel, and Member of Nymox Board of Directors. Mr. Doody joins Nymox from Pillsbury Winthrop Shaw Pittman LLP, where he was a partner in the Intellectual Property Group, and currently is Senior Counsel. Mr. Doody is a well-respected patent attorney with significant knowledge and experience in post-grant proceedings, patent infringement litigation, patent prosecution, licensing, opinions, and counseling. Mr. Doody has represented Nymox and its predecessor company in intellectual pr
IRVINE, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the "Company") is providing information to address requests it has received for further information concerning recent changes to the Company's Board of Directors ("Board") and the Company's management. Two former employees (the "Former Employees") of the Company proposed to the Company a potential transaction (the "Proposed Transaction"). The Company, its employees, and the Former Employees are bound by an obligation not to disclose any details of the Proposed Transaction. The terms of the Proposed Transaction were thoroughly reviewed and it was determined that it was not in the bes
IRVINE, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the "Company") is pleased to announce the appointment of Patrick Doody as Nymox Vice President, General Counsel, and Member of Nymox Board of Directors. Mr. Doody joins Nymox from Pillsbury Winthrop Shaw Pittman LLP, where he was a partner in the Intellectual Property Group, and currently is Senior Counsel. Mr. Doody is a well-respected patent attorney with significant knowledge and experience in post-grant proceedings, patent infringement litigation, patent prosecution, licensing, opinions, and counseling. Mr. Doody has represented Nymox and its predecessor company in intellectual pr
IRVINE, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") is pleased to announce the appointment of Christopher R. Riley as Chief Financial Officer (CFO) of Nymox. Mr. Riley is a globally experienced executive and entrepreneur with many notable successes and has held major positions in large well known corporations. He was CFO for Frito-Lay Australia where he was in charge of the snack food division, and during his tenure he was key executive responsible for the re-engineering of its distribution system. Mr. Riley served as CEO of PepsiCo Australia, where during his tenure revenue increased from $185MM to $265MM and market share in
6-K - NYMOX PHARMACEUTICAL CORP (0001018735) (Filer)
6-K - NYMOX PHARMACEUTICAL CORP (0001018735) (Filer)
6-K - NYMOX PHARMACEUTICAL CORP (0001018735) (Filer)
Gainers Caribou Biosciences (NASDAQ:CRBU) stock rose 50.7% to $6.15 during Thursday's regular session. The current volume of 75.4 million shares is 9750.6% of Caribou Biosciences's average full-day volume over the last 100 days (last updated at 13:37 EST). The company's market cap stands at $377.3 million. Aethlon Medical (NASDAQ:AEMD) stock moved upwards by 26.08% to $0.43. Aethlon Medical's stock is trading at a volume of 6.0 million shares as of 13:37 EST. This is 647.1% of its average full-day volume over the last 100 days. The company's market cap stands at $10.6 million. Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 16.93% to $2.17. As of 13:37 EST, this security is tradi
Gainers Caribou Biosciences, Inc. (NASDAQ:CRBU) shares jumped 58.1% to $6.45 after the company announced a $25 million equity investment from Pfizer. Mullen Automotive, Inc. (NASDAQ:MULN) shares climbed 53.1% to $ 0.2616 fter the company on Wednesday announced the retention of a law group to investigate possible naked short selling. The company also announced a buyback on Thursday. T2 Biosystems, Inc. (NASDAQ:TTOO) gained 27.5% to $0.0944. T2 Biosystems announced the conversion of approximately 20% of its term loan with entities affiliated with CRG Servicing LLC into its common stock and Series B convertible preferred stock. Borqs Technologies, Inc. (NASDAQ:BRQS) jumped 23.5% to $0.19